The problem was never generating leads. The bottleneck is validated results. It’s performing clinical trials proving efficacy. And this is where I think AI will have the biggest impact—-helping scientist, navigate study complexity and regulatory burden
"The problem was never generating leads" is an absurd statement without any reference to the quality of those leads. Ideally you want a system able to generate one more lead, the correct one.
I am sorry, but if you still have stupid humans these leads will end up going the same place all the leads go. Nowhere.
So what if DCTN1 is linked to Alzheimer's? All they will do is invent a drug to mess with the enzyme and it might only still help a small percentage of people and no one will be able to afford it.
It is well know that diet plays a large role in Alzheimer's[1] and is largely an issue of personal genetics and environment.
That's what top-tier scientists are good at.
So what if DCTN1 is linked to Alzheimer's? All they will do is invent a drug to mess with the enzyme and it might only still help a small percentage of people and no one will be able to afford it.
It is well know that diet plays a large role in Alzheimer's[1] and is largely an issue of personal genetics and environment.
[1] https://news.harvard.edu/gazette/story/2024/07/alzheimers-st...